$FRSX
Foresight Autonomous Holdings Ltd. Stock $frsx

$frsx Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 20-F Financial Statement

#000149315223009740 Filed on March 30, 2023

Income Statement

Concept	2022 Q4	2022	2021 Q4
Revenue	$99.00K	$550.0K	$80.00K
YoY Change	23.75%	358.33%
Cost Of Revenue	$44.00K	$252.0K	$32.00K
YoY Change	37.5%	276.12%
Gross Profit	$55.00K	$298.0K	$48.00K
YoY Change	14.58%	462.26%
Gross Profit Margin	55.56%	54.18%	60.0%
Selling, General & Admin	$1.558M	$6.219M	$1.517M
YoY Change	2.7%	6.71%	39.43%
% of Gross Profit	2832.73%	2086.91%	3160.42%
Research & Development	$3.035M	$11.53M	$2.647M
YoY Change	14.66%	13.41%	20.92%
% of Gross Profit	5518.18%	3870.47%	5514.58%
Depreciation & Amortization	$57.00K	$218.0K	$40.00K
YoY Change	42.5%	37.11%	-35.48%
% of Gross Profit	103.64%	73.15%	83.33%
Operating Expenses	$4.593M	$17.75M	$4.164M
YoY Change	10.3%	10.97%	27.07%
Operating Profit	-$4.538M	-$17.46M	-$4.116M
YoY Change	10.25%	9.47%
Interest Expense	$718.0K	-$2.208M	$390.0K
YoY Change	84.1%	-342.9%	-152.85%
% of Operating Profit
Other Income/Expense, Net		-$4.221M
YoY Change		-564.36%
Pretax Income	-$3.820M	-$21.68M	-$3.726M
YoY Change	2.52%	44.16%	-7.2%
Income Tax
% Of Pretax Income
Net Earnings	-$3.820M	-$21.68M	-$3.726M
YoY Change	2.52%	44.16%	-7.2%
Net Earnings / Revenue	-3858.59%	-3941.09%	-4657.5%
Basic Earnings Per Share		-$0.07
Diluted Earnings Per Share	-$0.01	-$0.07	-$11.74K
COMMON SHARES
Basic Shares Outstanding	323.0M shares	322.8M shares
Diluted Shares Outstanding		322.8M shares

Balance Sheet

Concept	2022 Q4	2022	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$26.39M	$26.39M	$45.71M
YoY Change	-42.27%	-42.27%	3.94%
Cash & Equivalents	$19.17M	$19.17M	$28.07M
Short-Term Investments	$7.218M	$7.218M	$17.53M
Other Short-Term Assets	$102.0K	$482.0K
YoY Change		69.72%
Inventory
Prepaid Expenses	$380.0K		$284.0K
Receivables
Other Receivables	$842.0K		$660.0K
Total Short-Term Assets	$27.34M	$27.34M	$46.37M
YoY Change	-41.05%	-41.05%	4.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$598.0K	$2.754M	$3.097M
YoY Change	-80.69%	-11.08%	102.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$2.804M	$2.804M	$4.011M
YoY Change	-30.09%	-30.09%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$5.558M	$5.558M	$7.108M
YoY Change	-21.81%	-21.81%	28.26%
TOTAL ASSETS
Total Short-Term Assets	$27.34M	$27.34M	$46.37M
Total Long-Term Assets	$5.558M	$5.558M	$7.108M
Total Assets	$32.89M	$32.89M	$53.48M
YoY Change	-38.5%	-38.5%	7.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.107M	$315.0K	$253.0K
YoY Change	732.81%	24.51%	-35.29%
Accrued Expenses	$299.0K	$1.792M	$241.0K
YoY Change	24.07%	26.2%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$527.0K	$527.0K	$587.0K
YoY Change	-10.22%	-10.22%	37.47%
Total Short-Term Liabilities	$2.634M	$2.634M	$2.705M
YoY Change	-2.62%	-2.62%	33.58%
LONG-TERM LIABILITIES
Long-Term Debt	$1.476M	$1.476M	$2.143M
YoY Change	-31.12%	-31.12%	151.23%
Other Long-Term Liabilities	$1.476M	$1.476M
YoY Change		-31.12%
Total Long-Term Liabilities	$1.476M	$1.476M	$2.143M
YoY Change	-31.12%	-31.12%	151.23%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.634M	$2.634M	$2.705M
Total Long-Term Liabilities	$1.476M	$1.476M	$2.143M
Total Liabilities	$4.110M	$4.563M	$5.076M
YoY Change	-19.03%	-10.11%	71.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$101.5M		-$79.80M
YoY Change	27.16%
Common Stock	$0.00		$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$28.33M	$28.33M	$48.41M
YoY Change
Total Liabilities & Shareholders Equity	$32.89M	$32.89M	$53.48M
YoY Change	-38.5%	-38.5%	7.13%

Cashflow Statement

Concept	2022 Q4	2022	2021 Q4
OPERATING ACTIVITIES
Net Income	-$3.820M	-$21.68M	-$3.726M
YoY Change	2.52%	44.16%	-7.2%
Depreciation, Depletion And Amortization	$57.00K	$218.0K	$40.00K
YoY Change	42.5%	37.11%	-35.48%
Cash From Operating Activities	-$3.954M	-$17.06M	-$3.150M
YoY Change	25.52%	40.68%	5.46%
INVESTING ACTIVITIES
Capital Expenditures	$31.00K	$313.0K	-$117.0K
YoY Change	-126.5%	-233.19%	5750.0%
Acquisitions
YoY Change
Other Investing Activities	$10.53M	$9.296M	-$789.0K
YoY Change	-1434.22%	-175.29%	3187.5%
Cash From Investing Activities	$10.50M	$8.983M	-$906.0K
YoY Change	-1258.5%	-171.4%	3384.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000		0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-3.954M	-$17.06M	-3.150M
Cash From Investing Activities	10.50M	$8.983M	-906.0K
Cash From Financing Activities	0.000		0.000
Net Change In Cash	6.542M	-$8.913M	-4.056M
YoY Change	-261.29%	-15.49%	-113.83%
FREE CASH FLOW
Cash From Operating Activities	-$3.954M	-$17.06M	-$3.150M
Capital Expenditures	$31.00K	$313.0K	-$117.0K
Free Cash Flow	-$3.985M	-$17.37M	-$3.033M
YoY Change	31.39%	46.09%	1.61%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001691221
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2020	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2020	us-gaap	Gross Profit GrossProfit		usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt		usd
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt		usd
CY2021	FRSX	Investment In Simple Agreement For Future Equity InvestmentInSimpleAgreementForFutureEquity		usd
CY2020	FRSX	Investment In Simple Agreement For Future Equity InvestmentInSimpleAgreementForFutureEquity		usd
CY2021	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi		usd
CY2020	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2022	us-gaap	Income Loss From Equity Method Investments Net Of Dividends Or Distributions IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions		usd
CY2021	us-gaap	Income Loss From Equity Method Investments Net Of Dividends Or Distributions IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions		usd
CY2022	FRSX	Accrued Issuance Expenses Recorded In Shareholders Equity AccruedIssuanceExpensesRecordedInShareholdersEquity		usd
CY2021	FRSX	Accrued Issuance Expenses Recorded In Shareholders Equity AccruedIssuanceExpensesRecordedInShareholdersEquity		usd
CY2021	FRSX	Conversion Of Simple Agreement For Future Equity To Investment In Equity Securities ConversionOfSimpleAgreementForFutureEquityToInvestmentInEquitySecurities		usd
CY2020	FRSX	Conversion Of Simple Agreement For Future Equity To Investment In Equity Securities ConversionOfSimpleAgreementForFutureEquityToInvestmentInEquitySecurities		usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent		usd
CY2022	FRSX	New Operating Lease Assets Obtained In Exchange For Operating Lease Liabilities NewOperatingLeaseAssetsObtainedInExchangeForOperatingLeaseLiabilities		usd
CY2020	FRSX	Less Participation In Grants Researchand Development Total LessParticipationInGrantsResearchandDevelopmentTotal		usd
CY2022	FRSX	Sales Of Prototypes SalesOfPrototypes		usd
CY2021	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense		usd
CY2020	FRSX	Bank Interest Income BankInterestIncome		usd
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	dei	Document Type DocumentType	20-F
CY2022	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38094
CY2022	dei	Entity Registrant Name EntityRegistrantName	FORESIGHT AUTONOMOUS HOLDINGS LTD.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	(Jurisdiction of incorporation or organization)
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	7 Golda Meir
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Ness Ziona
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	7403650
CY2022	dei	Entity Address Country EntityAddressCountry	IL
CY2022	dei	Trading Symbol TradingSymbol	FRSX
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Security12b Title Security12bTitle	Ordinary Shares, no par value
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	322979556	shares
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022	dei	Auditor Firm AuditorFirmId	1197
CY2022	dei	Auditor Name AuditorName	Brightman Almagor Zohar & Co.
CY2022	dei	Auditor Location AuditorLocation	Tel Aviv, Israel
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19173000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28073000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	102000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	115000	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	7216000	usd
CY2021Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	17513000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	12000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	842000	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	660000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	27335000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	46373000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2156000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2594000	usd
CY2022Q4	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	2804000	usd
CY2021Q4	us-gaap	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	4011000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	598000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	503000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	5558000	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	7108000	usd
CY2022Q4	us-gaap	Assets Assets	32893000	usd
CY2021Q4	us-gaap	Assets Assets	53481000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	315000	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	253000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	527000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	587000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1792000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1865000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2634000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2705000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1476000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2143000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	4110000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	4848000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	322979556	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	322979556	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	322652016	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	322652016	shares
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	129810000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	128209000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-101480000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-79804000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	28330000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	48405000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	453000	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	228000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28783000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	48633000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	32893000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53481000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	550000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	120000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	252000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	67000	usd
CY2022	us-gaap	Gross Profit GrossProfit	298000	usd
CY2021	us-gaap	Gross Profit GrossProfit	53000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11534000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10170000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8563000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2230000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1848000	usd
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1268000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3989000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3980000	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3005000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-17455000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-15945000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-12836000	usd
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2718000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4221000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	909000	usd
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	179000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-21676000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-15036000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-15375000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	322817000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	321356000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	219913000	shares
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	16288000	usd
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	44707000	usd
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	263000	usd
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1162000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-15375000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	47045000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13508000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	57000	usd
CY2021	FRSX	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	595000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2464000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-15036000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	48633000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	48633000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1822000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-21676000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28783000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28783000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-21676000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-15036000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-15375000	usd
CY2022	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	4619000	usd
CY2021	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	2911000	usd
CY2020	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	3880000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17057000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12125000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11495000	usd
CY2022	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	-10297000	usd
CY2021	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	12347000	usd
CY2020	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	-67000	usd
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	68000	usd
CY2022	FRSX	Investment In Simple Agreement For Future Equity InvestmentInSimpleAgreementForFutureEquity	286000	usd
CY2022	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	715000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	313000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	235000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	50000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	8983000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12582000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	85000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13508000	usd
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	45017000	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	595000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	57000	usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	263000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14160000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	45280000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-839000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-37000	usd
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8913000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10584000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	33945000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28188000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38772000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4827000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19275000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28188000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38772000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1826000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2464000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	1162000	usd
CY2022	us-gaap	Depreciation Depreciation	218000	usd
CY2021	us-gaap	Depreciation Depreciation	159000	usd
CY2020	us-gaap	Depreciation Depreciation	254000	usd
CY2020	us-gaap	Income Loss From Equity Method Investments Net Of Dividends Or Distributions IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions	-2718000	usd
CY2022	FRSX	Revaluation Of Marketable Securities RevaluationOfMarketableSecurities	2217000	usd
CY2021	FRSX	Revaluation Of Marketable Securities RevaluationOfMarketableSecurities	30000	usd
CY2020	FRSX	Revaluation Of Marketable Securities RevaluationOfMarketableSecurities	-87000	usd
CY2022	FRSX	Exchange Rate Changes On Cash And Cash Equivalents ExchangeRateChangesOnCashAndCashEquivalents	839000	usd
CY2021	FRSX	Exchange Rate Changes On Cash And Cash Equivalents ExchangeRateChangesOnCashAndCashEquivalents	37000	usd
CY2020	FRSX	Exchange Rate Changes On Cash And Cash Equivalents ExchangeRateChangesOnCashAndCashEquivalents	-75000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	182000	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	259000	usd
CY2020	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-212000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	62000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-138000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-296000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-289000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-33000	usd
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	60000	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-72000	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	651000	usd
CY2020	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-68000	usd
CY2022	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	4619000	usd
CY2021	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	2911000	usd
CY2020	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	3880000	usd
CY2020	FRSX	Accrued Issuance Expenses Recorded In Shareholders Equity AccruedIssuanceExpensesRecordedInShareholdersEquity	310000	usd
CY2022	FRSX	Conversion Of Simple Agreement For Future Equity To Investment In Equity Securities ConversionOfSimpleAgreementForFutureEquityToInvestmentInEquitySecurities	286000	usd
CY2022	FRSX	American Depository Shares Description AmericanDepositorySharesDescription	The ADSs are listed on The Nasdaq Capital Market, and the ratio of the Company’s Ordinary Shares to ADSs is 5:1.
CY2016Q1	FRSX	Ordinary Shares Issued Percentage OrdinarySharesIssuedPercentage	0.6450	pure
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_845_eus-gaap--UseOfEstimates_zsB1azxFJlyi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zv3WtKG3cMga">Use of estimates in the preparation of financial statements</span>:</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company’s management believes that the estimates, judgment, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect reported amounts and disclosures made. Actual results could differ from those estimates.</span></p>
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-21676000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-15036000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-15375000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022	FRSX	Earnings Per Share Basic And Diluted American Depository Shares EarningsPerShareBasicAndDilutedAmericanDepositoryShares	-0.35
CY2021	FRSX	Earnings Per Share Basic And Diluted American Depository Shares EarningsPerShareBasicAndDilutedAmericanDepositoryShares	-0.25
CY2020	FRSX	Earnings Per Share Basic And Diluted American Depository Shares EarningsPerShareBasicAndDilutedAmericanDepositoryShares	-0.35
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	322817000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	321356000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	219913000	shares
CY2022	FRSX	Weighted Average Number Of Share Outstanding Basic And Diluted In American Depository Shares WeightedAverageNumberOfShareOutstandingBasicAndDilutedInAmericanDepositoryShares	64563000	shares
CY2021	FRSX	Weighted Average Number Of Share Outstanding Basic And Diluted In American Depository Shares WeightedAverageNumberOfShareOutstandingBasicAndDilutedInAmericanDepositoryShares	64271000	shares
CY2020	FRSX	Weighted Average Number Of Share Outstanding Basic And Diluted In American Depository Shares WeightedAverageNumberOfShareOutstandingBasicAndDilutedInAmericanDepositoryShares	43983000	shares
CY2022Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	225000	usd
CY2021Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	240000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	380000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	284000	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	237000	usd
CY2021Q4	us-gaap	Other Receivables OtherReceivables	136000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	842000	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	660000	usd
CY2016Q2	FRSX	Description Of Share Purchase Agreement DescriptionOfSharePurchaseAgreement	During 2016, the Company entered into a share purchase agreement to acquire 32% of the share capital of Rail Vision Ltd (“Rail Vision”) and three types of warrants to purchase ordinary shares of Rail Vision.
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	4011000	usd
CY2022	FRSX	Revaluation To Fair Value Through Profit Or Loss RevaluationToFairValueThroughProfitOrLoss	-2208000	usd
CY2022	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	715000	usd
CY2022	FRSX	Conversion Of Simple Agreement For Future Equity To Investment In Equity Securities ConversionOfSimpleAgreementForFutureEquityToInvestmentInEquitySecurities	286000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	2804000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1674000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1386000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1076000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	883000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	598000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	503000	usd
CY2022	us-gaap	Depreciation Depreciation	218000	usd
CY2021	us-gaap	Depreciation Depreciation	159000	usd
CY2022	us-gaap	General Discussion Of Pension And Other Postretirement Benefits GeneralDiscussionOfPensionAndOtherPostretirementBenefits	Pursuant to section 14 of the Israeli Severance Pay Law, 5723-1963, the Company’s employees covered under this section are entitled to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with pension companies.
CY2022Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	1493000	usd
CY2021Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	1179000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	299000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	241000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	445000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1792000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1865000	usd
CY2022	FRSX	Royalty Description RoyaltyDescription	Magna obtained grants from the Israeli Innovation Authority (the “IIA”) for participation in research and development programs for the years 2011 through 2013, and, in return, further to an acquisition transaction between the Company and Magna, the Company is obligated to pay royalties amounting to 3% to 5% of its future sales up to the amount of the grant.
CY2022Q4	us-gaap	Grants Receivable GrantsReceivable	603000	usd
CY2021Q4	us-gaap	Grants Receivable GrantsReceivable	683000	usd
CY2020Q4	us-gaap	Grants Receivable GrantsReceivable	661000	usd
CY2022	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The Company and its subsidiaries, Foresight Ltd. and Eye Net, currently has 3-year leases for their offices with options to extend the leases for another 3 years. The lease for Foresight Ltd. and Eye Net ends on March 31, 2027 and December 15, 2027, respectively. The Company also currently leases several vehicles, each for a term of 3 years. The Company has no finance leases.
CY2022	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	options to extend the leases for another 3 years.
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	550000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	527000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	491000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	483000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	483000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	218000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2202000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	199000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2003000	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1662000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1826000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2464000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	1162000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	225000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	154000	usd
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	74000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1601000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2310000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1088000	usd
CY2022	FRSX	Payroll Research And Development Related Expenses PayrollResearchAndDevelopmentRelatedExpenses	8778000	usd
CY2021	FRSX	Payroll Research And Development Related Expenses PayrollResearchAndDevelopmentRelatedExpenses	7556000	usd
CY2020	FRSX	Payroll Research And Development Related Expenses PayrollResearchAndDevelopmentRelatedExpenses	5922000	usd
CY2022	FRSX	Subcontracted Work And Consulting Fee Expenses Related To Research And Development SubcontractedWorkAndConsultingFeeExpensesRelatedToResearchAndDevelopment	1523000	usd
CY2021	FRSX	Subcontracted Work And Consulting Fee Expenses Related To Research And Development SubcontractedWorkAndConsultingFeeExpensesRelatedToResearchAndDevelopment	1751000	usd
CY2020	FRSX	Subcontracted Work And Consulting Fee Expenses Related To Research And Development SubcontractedWorkAndConsultingFeeExpensesRelatedToResearchAndDevelopment	1534000	usd
CY2022	FRSX	Share Based Payments To Service Provider Related To Research And Development ShareBasedPaymentsToServiceProviderRelatedToResearchAndDevelopment	57000	usd
CY2021	FRSX	Share Based Payments To Service Provider Related To Research And Development ShareBasedPaymentsToServiceProviderRelatedToResearchAndDevelopment	118000	usd
CY2020	FRSX	Share Based Payments To Service Provider Related To Research And Development ShareBasedPaymentsToServiceProviderRelatedToResearchAndDevelopment	67000	usd
CY2022	FRSX	Rent And Office Maintenance For Research And Development RentAndOfficeMaintenanceForResearchAndDevelopment	1068000	usd
CY2021	FRSX	Rent And Office Maintenance For Research And Development RentAndOfficeMaintenanceForResearchAndDevelopment	810000	usd
CY2020	FRSX	Rent And Office Maintenance For Research And Development RentAndOfficeMaintenanceForResearchAndDevelopment	671000	usd
CY2022	FRSX	Travel Expenses Related To Research And Development TravelExpensesRelatedToResearchAndDevelopment	141000	usd
CY2021	FRSX	Travel Expenses Related To Research And Development TravelExpensesRelatedToResearchAndDevelopment	44000	usd
CY2020	FRSX	Travel Expenses Related To Research And Development TravelExpensesRelatedToResearchAndDevelopment	54000	usd
CY2022	FRSX	Other Research And Development OtherResearchAndDevelopment	362000	usd
CY2021	FRSX	Other Research And Development OtherResearchAndDevelopment	309000	usd
CY2020	FRSX	Other Research And Development OtherResearchAndDevelopment	415000	usd
CY2022	FRSX	Less Participation In Grants Researchand Development Total LessParticipationInGrantsResearchandDevelopmentTotal	-395000	usd
CY2021	FRSX	Less Participation In Grants Researchand Development Total LessParticipationInGrantsResearchandDevelopmentTotal	-351000	usd
CY2021	FRSX	Sales Of Prototypes SalesOfPrototypes	-67000	usd
CY2020	FRSX	Sales Of Prototypes SalesOfPrototypes	-100000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11534000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10170000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8563000	usd
CY2022	FRSX	Payroll Marketing And Sales Related Expenses PayrollMarketingAndSalesRelatedExpenses	1318000	usd
CY2021	FRSX	Payroll Marketing And Sales Related Expenses PayrollMarketingAndSalesRelatedExpenses	1273000	usd
CY2020	FRSX	Payroll Marketing And Sales Related Expenses PayrollMarketingAndSalesRelatedExpenses	833000	usd
CY2022	FRSX	Marketing And Sales Exhibitions Conventions And Travel Expenses MarketingAndSalesExhibitionsConventionsAndTravelExpenses	302000	usd
CY2021	FRSX	Marketing And Sales Exhibitions Conventions And Travel Expenses MarketingAndSalesExhibitionsConventionsAndTravelExpenses	42000	usd
CY2020	FRSX	Marketing And Sales Exhibitions Conventions And Travel Expenses MarketingAndSalesExhibitionsConventionsAndTravelExpenses	175000	usd
CY2022	FRSX	Marketing And Sales Consultants Fees MarketingAndSalesConsultantsFees	558000	usd
CY2021	FRSX	Marketing And Sales Consultants Fees MarketingAndSalesConsultantsFees	394000	usd
CY2020	FRSX	Marketing And Sales Consultants Fees MarketingAndSalesConsultantsFees	178000	usd
CY2022	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	52000	usd
CY2021	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	139000	usd
CY2020	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	82000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2230000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1848000	usd
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1268000	usd
CY2022	FRSX	Payroll General And Administrative Related Expenses PayrollGeneralAndAdministrativeRelatedExpenses	1756000	usd
CY2021	FRSX	Payroll General And Administrative Related Expenses PayrollGeneralAndAdministrativeRelatedExpenses	1748000	usd
CY2020	FRSX	Payroll General And Administrative Related Expenses PayrollGeneralAndAdministrativeRelatedExpenses	1342000	usd
CY2022	FRSX	Share Based Payments To Service Providers For General And Administrative Expenses ShareBasedPaymentsToServiceProvidersForGeneralAndAdministrativeExpenses	215000	usd
CY2021	FRSX	Share Based Payments To Service Providers For General And Administrative Expenses ShareBasedPaymentsToServiceProvidersForGeneralAndAdministrativeExpenses	268000	usd
CY2020	FRSX	Share Based Payments To Service Providers For General And Administrative Expenses ShareBasedPaymentsToServiceProvidersForGeneralAndAdministrativeExpenses	128000	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	1340000	usd
CY2021	us-gaap	Professional Fees ProfessionalFees	1207000	usd
CY2020	us-gaap	Professional Fees ProfessionalFees	926000	usd
CY2022	FRSX	Directors Fees And Insurance DirectorsFeesAndInsurance	405000	usd
CY2021	FRSX	Directors Fees And Insurance DirectorsFeesAndInsurance	494000	usd
CY2020	FRSX	Directors Fees And Insurance DirectorsFeesAndInsurance	348000	usd
CY2022	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	8000	usd
CY2020	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	14000	usd
CY2022	FRSX	Rent And Office Maintenance RentAndOfficeMaintenance	175000	usd
CY2021	FRSX	Rent And Office Maintenance RentAndOfficeMaintenance	212000	usd
CY2020	FRSX	Rent And Office Maintenance RentAndOfficeMaintenance	146000	usd
CY2022	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	90000	usd
CY2021	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	51000	usd
CY2020	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	101000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3989000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3980000	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3005000	usd
CY2022	us-gaap	Gain Loss On Securitization Of Financial Assets GainLossOnSecuritizationOfFinancialAssets	-2208000	usd
CY2021	us-gaap	Gain Loss On Securitization Of Financial Assets GainLossOnSecuritizationOfFinancialAssets	-10000	usd
CY2020	us-gaap	Gain Loss On Securitization Of Financial Assets GainLossOnSecuritizationOfFinancialAssets	85000	usd
CY2022	FRSX	Bank Interest Income BankInterestIncome	189000	usd
CY2021	FRSX	Bank Interest Income BankInterestIncome	887000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2194000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	14000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	18000	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	94000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4221000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	909000	usd
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	179000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.23	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.23	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.23	pure
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	68870000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	68870000	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	51683000	usd
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	37951000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15840000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11887000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8729000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15840000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11887000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8729000	usd
CY2022	FRSX	Subcontracted Work And Consulting And Related Parties SubcontractedWorkAndConsultingAndRelatedParties	748000	usd
CY2021	FRSX	Subcontracted Work And Consulting And Related Parties SubcontractedWorkAndConsultingAndRelatedParties	823000	usd
CY2020	FRSX	Subcontracted Work And Consulting And Related Parties SubcontractedWorkAndConsultingAndRelatedParties	672000	usd
CY2022	FRSX	Share Based Payments To Service Provider And Related Parties ShareBasedPaymentsToServiceProviderAndRelatedParties	56000	usd
CY2021	FRSX	Share Based Payments To Service Provider And Related Parties ShareBasedPaymentsToServiceProviderAndRelatedParties	118000	usd
CY2020	FRSX	Share Based Payments To Service Provider And Related Parties ShareBasedPaymentsToServiceProviderAndRelatedParties	67000	usd
CY2022	FRSX	Transactions And Balances With Interest Related Parties TransactionsAndBalancesWithInterestRelatedParties	804000	usd
CY2021	FRSX	Transactions And Balances With Interest Related Parties TransactionsAndBalancesWithInterestRelatedParties	941000	usd
CY2020	FRSX	Transactions And Balances With Interest Related Parties TransactionsAndBalancesWithInterestRelatedParties	739000	usd
CY2022Q4	us-gaap	Due To Other Related Parties Current And Noncurrent DueToOtherRelatedPartiesCurrentAndNoncurrent	63000	usd
CY2021Q4	us-gaap	Due To Other Related Parties Current And Noncurrent DueToOtherRelatedPartiesCurrentAndNoncurrent	75000	usd
CY2022Q4	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	63000	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	75000	usd

Files In Submission

Name	View Source	Status
frsx-20221231_pre.xml	Edgar Link	unprocessable
0001493152-23-009740-index-headers.html	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
0001493152-23-009740-index.html	Edgar Link	pending
0001493152-23-009740.txt	Edgar Link	pending
0001493152-23-009740-xbrl.zip	Edgar Link	pending
ex12-1.htm	Edgar Link	pending
ex12-2.htm	Edgar Link	pending
ex13-1.htm	Edgar Link	pending
ex13-2.htm	Edgar Link	pending
ex15-1.htm	Edgar Link	pending
ex2-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fin_001.jpg	Edgar Link	pending
fin_003.jpg	Edgar Link	pending
form20-f.htm	Edgar Link	pending
form20-f_002.jpg	Edgar Link	pending
form20-f_003.jpg	Edgar Link	pending
form20-f_004.jpg	Edgar Link	pending
form20-f_005.jpg	Edgar Link	pending
form20-f_006.jpg	Edgar Link	pending
form20-f_007.jpg	Edgar Link	pending
form20-f_008.jpg	Edgar Link	pending
form20-f_009.jpg	Edgar Link	pending
form20-f_01.jpg	Edgar Link	pending
form20-f_010.jpg	Edgar Link	pending
frsx-20221231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
frsx-20221231_cal.xml	Edgar Link	unprocessable
frsx-20221231_def.xml	Edgar Link	unprocessable
frsx-20221231_lab.xml	Edgar Link	unprocessable
form20-f_htm.xml	Edgar Link	completed
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FRSX
Foresight Autonomous Holdings Ltd. Stock $frsx

2022 Q4 Form 20-F Financial Statement

#000149315223009740 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FRSX Foresight Autonomous Holdings Ltd. Stock $frsx

2022 Q4 Form 20-F Financial Statement

#000149315223009740 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FRSX
Foresight Autonomous Holdings Ltd. Stock $frsx